JP2014097964A5 - - Google Patents

Download PDF

Info

Publication number
JP2014097964A5
JP2014097964A5 JP2012251831A JP2012251831A JP2014097964A5 JP 2014097964 A5 JP2014097964 A5 JP 2014097964A5 JP 2012251831 A JP2012251831 A JP 2012251831A JP 2012251831 A JP2012251831 A JP 2012251831A JP 2014097964 A5 JP2014097964 A5 JP 2014097964A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
deuterium
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012251831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014097964A (ja
JP6146990B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2012251831A priority Critical patent/JP6146990B2/ja
Priority claimed from JP2012251831A external-priority patent/JP6146990B2/ja
Publication of JP2014097964A publication Critical patent/JP2014097964A/ja
Publication of JP2014097964A5 publication Critical patent/JP2014097964A5/ja
Application granted granted Critical
Publication of JP6146990B2 publication Critical patent/JP6146990B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012251831A 2012-11-16 2012-11-16 重水素化されたcftr増強物質 Active JP6146990B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012251831A JP6146990B2 (ja) 2012-11-16 2012-11-16 重水素化されたcftr増強物質

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012251831A JP6146990B2 (ja) 2012-11-16 2012-11-16 重水素化されたcftr増強物質

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017022718A Division JP2017105824A (ja) 2017-02-10 2017-02-10 重水素化されたcftr増強物質

Publications (3)

Publication Number Publication Date
JP2014097964A JP2014097964A (ja) 2014-05-29
JP2014097964A5 true JP2014097964A5 (enExample) 2016-01-07
JP6146990B2 JP6146990B2 (ja) 2017-06-14

Family

ID=50940312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012251831A Active JP6146990B2 (ja) 2012-11-16 2012-11-16 重水素化されたcftr増強物質

Country Status (1)

Country Link
JP (1) JP6146990B2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN105130948A (zh) 2010-04-22 2015-12-09 弗特克斯药品有限公司 制备环烷基甲酰胺基-吲哚化合物的方法
JP6543268B2 (ja) 2014-04-15 2019-07-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 嚢胞性線維症膜コンダクタンス調節因子が媒介する疾患を処置するための医薬組成物
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
TWI881480B (zh) 2015-06-30 2025-04-21 美商伊格集團國際股份有限公司 克立咪唑(clemizole)化合物於預防及治療肝癌之用途
HUP1600271A2 (hu) 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei
US10206915B2 (en) 2016-04-25 2019-02-19 Druggability Technologies Ip Holdco Limited Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US10383865B2 (en) 2016-04-25 2019-08-20 Druggability Technologies Ip Holdco Limited Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
HUP1600270A2 (hu) 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei
EP3476850B1 (en) 2016-07-25 2024-12-11 Shenzhen TargetRx, Inc. Substituted boric acid compound, pharmaceutical composition comprising same, and application thereof
JP2017105824A (ja) * 2017-02-10 2017-06-15 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたcftr増強物質
CN117924170A (zh) * 2017-12-01 2024-04-26 弗特克斯药品有限公司 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
JP6654223B2 (ja) * 2018-08-13 2020-02-26 バーテックス ファーマシューティカルズ (ヨーロッパ) リミテッド 重水素化されたcftr増強物質
CN115350184A (zh) * 2020-01-10 2022-11-18 康圣博施医药有限公司 药物的治疗组合以及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1087725C (zh) * 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
RS51550B (sr) * 2002-04-08 2011-06-30 Pfizer Inc. Derivati tropana kao modulatori ccr5
CN100351259C (zh) * 2002-06-20 2007-11-28 Icvec有限公司 含硫的磷脂衍生物
CN101891680B (zh) * 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
DK3235812T3 (da) * 2011-05-18 2019-11-25 Vertex Pharmaceuticals Europe Ltd Deutererede derivater af ivacaftor

Similar Documents

Publication Publication Date Title
JP2014515351A5 (enExample)
JP2015528020A5 (enExample)
JP2018534348A5 (enExample)
JP2013537203A5 (enExample)
JP2015145426A5 (enExample)
JP2013032389A5 (enExample)
JP2014500861A5 (enExample)
JP2015512432A5 (enExample)
JP2013542261A5 (enExample)
JP2011037841A5 (enExample)
JP2016500111A5 (enExample)
JP2013509429A5 (enExample)
JP2017537066A5 (enExample)
JP2010001302A5 (enExample)
RU2018114447A (ru) Введение дейтерированных усилителей cftr
JP2012072150A5 (enExample)
JP2014515013A5 (enExample)
JP2015537020A5 (enExample)
JP2013510120A5 (enExample)
JP2016529306A5 (enExample)
JP2013539448A5 (enExample)
JP2016540749A5 (enExample)
JP2012519182A5 (enExample)
JP2012532883A5 (enExample)
JP2014503593A5 (enExample)